Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-11-20
1998-12-22
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514813, A61K 31485
Patent
active
058520325
ABSTRACT:
A method of treating a subject afflicted with nicotine dependence with the opiate antagonist, nalmefene is described. The subjects will not gain significant amounts of weight as a result of smoking reduction or cessation.
REFERENCES:
patent: 4946848 (1990-08-01), Tuttle
patent: 4990617 (1991-02-01), Boswell
patent: 4994466 (1991-02-01), Sherman
patent: 5028612 (1991-07-01), Glover
patent: 5057322 (1991-10-01), Frost
patent: 5086058 (1992-02-01), Sinclair
patent: 5552406 (1996-09-01), Mendelson
patent: 5574052 (1996-11-01), Rose
patent: 5593684 (1997-01-01), Baker
Malin et al., Psychopharmacology (1993), 112(2-3), 339-42.
Aceto et al., Nicotine's opioid and anti-opioid interactions: proposed role in smoking behavior, Eur. J. of Pharmacology, vol. 248, pp. 333-335, 1993.
Chiodera et al., Naloxone Decreases the Inhibiting Effect of Ethanol on the Release of Arginine-Vasopressin Induced by Cigarette Smoking in Man, Metabolism, vol. 36, No. 8, pp. 804-806, Aug. 1987.
Chiodera et al., Gamma-Aminobutyric Acid mediation of the Inhibitory Effect of Endogenous Opioids on the Arginine Vasopressin and Oxytocin Responses to Nicotine From Cigarette Smoking, Metabolism, vol. 42, No. 6, 762-765, Jun. 1983.
Corrigall et al., Opiate antagonists reduce cocaine but not nicotine self-administration, Psychopharmacology, vol. 104, pp. 167-170, 1991.
P.F. D'Arcy, Tobacco Smoking and Drugs: A Clinically Important Interaction, Drug Intelligence and Clinical Pharmacy, vol. 18, pp. 302-307, Apr. 1984.
Karras et al., Naloxone Reduces Cigarette Smoking, Life Sciences, vol. 27, pp. 1541-1545, 1980.
Little et al., Patterns of Multiple Substance Abuse During Pregnancy: Implications for Mother and Fetus, Southern Medical Journal, vol. 83, No. 5, pp. 507-509, May 1990.
Mason et al., A Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of Oral Nalmefene HC1 for Alcohol Dependence, Alcohol Clin Exp Res., vol. 18, No. 5, pp. 1162-1167, 1994.
Nemeth-Coslett et al., Naloxone does not affect cigarette smoking, Psychopharmacology vol. 89, pp. 261-264, 1986.
O'Malley et al., Naltrexone and Coping Skills Therapy for Alcohol Dependence, Arch Gen Psychiatry, vol. 49, pp. 881-887, Nov. 1992.
Santiago et al., Opioids and breathing, J. Appl. Physiol., vol. 59, No. 6, pp. 1675-1685, 1985.
Seckl et al., Endogenous Opioids Inhibit Oxytocin Release During Nicotine-Stimulated Secretion of Vasopressin in Man, Clinical Endocrinology, vol. 28, pp. 509-514, 1988.
Volpicelli et al., Naltrexone in the Treatment of Alcohol Dependence, Arch Gen Psychiatry, vol. 49, pp. 876-880, Nov. 1992.
Spivack Phyllis G.
The University of Miami
LandOfFree
Method of treating nicotine dependence does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating nicotine dependence, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating nicotine dependence will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2047984